somewordstoolate/Q2CRBench-3 huggingface dataset:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on maximally tolerated dose of LEF monotherapy who are NOT at target, and have previously failed MTX (due to an inadequate response or adverse events), add SSZ and HCQ, or add a boDMARD, or add tsDMARD?
Population: Patients with RA on maximally tolerated dose of LEF monotherapy who are not at target, and have previously failed MTX (due to an inadequate response or adverse events)
Intervention: Add SSZ and HCQ
Comparator: Add TNF Inhibitor
Add Abatacept
Add Rituximab
Add IL-6 Receptor Inhibitor
Add JAK Inhibitor
Outcomes:
add TNF Inhibitor: Disease activity (follow up: 6 months; assessed with: ACR20)
Disease activity (follow up: 6 months; assessed with: ACR50)
Disease activity (follow up: 6 months; assessed with: ACR70)
Disease activity (follow up: 6 months; assessed with: DAS28-ESR)
Remission (follow up: 6 months; assessed with: DAS28-CRP < 2.6)
Radiographic progression (follow up: 6 months; assessed with: mTSS)
Disability (follow up: 6 months; assessed with: HAQ-DI)
Malignancy (from SRs of harms)
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on DMARD(s) who are NOT at target switch to another DMARD versus add a 2nd DMARD?
Population: Patients with RA on non-biologic DMARD(s) who are not at target
Intervention: Switch to another DMARD
Comparator: Add another DMARD
Outcomes:
Add another DMARD: Disease activity (follow up: range 4 months to 2 years; assessed with: ACR 20)
Disease activity (follow up: range 4 months to 2 years; assessed with: ACR 50)
Disease activity (follow up: range 4 months to 2 years; assessed with: ACR 70)
Disease activity (follow up: range 4 months to 2 years; assessed with: DAS28 or DAS44 (lower values --> benefit) (values>0.2 are considered clinically important)
Remission (follow up: range 4 months to 1 year; assessed with: DAS remission < 2.6 )
Flare (follow up: 1 months)
Radiographic progression (follow up: 6 months; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)
Pain (follow up: range 4 months to 12 months; assessed with: VAS pain (0-100) (Lower values – > benefit) (MCID -11.9)
Disability (follow up: range 4 months to 2 years; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)
Fatigue (follow up: 1 year; assessed with: FACIT-F (Higher values – > benefit) (MCID 15.9)
Quality of Life (follow up: 1 year; assessed with:  SF-36 MCS (Higher values – > benefit) (MCID 3.1)
Quality of Life (follow up: 1 year; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)
Quality of Life (follow up: range 4 months to 2 years; assessed with: RAQol or EQ-5D VAS (lower values --> benefit) (values>0.2 are considered clinically important)
Withdrawal due to lack of efficacy (follow up: range 4 months to 1 year)
Withdrawal due to adverse events (follow up: range 3 months to 2 years)
Serious adverse events (follow up: range 3 months to 2 years)
Malignancy (follow up: range 4 months to 2 years)
Death (follow up: range 4 months to 2 years)
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on DMARD(s) who are NOT at target and who are being switched to a second DMARD, have short-term GCs (≤ 3 months) added, long-term GCs (> 3 months) added versus no GCs added?
Population: Patients with RA on DMARD(s) who are not at target and who are being switched to a second DMARD
Intervention: Add short-term GCs (≤ 3 months)
Comparator: Add long-term GCs (> 3 months)
No GCs added
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on DMARD(s) who are NOT at target and whom a second DMARD is being added, have short-term GCs (≤ 3 months) added, long-term GCs (> 3 months) added versus no GCs added?
Population: Patients with RA on DMARD(s) who are not at target and whom a second DMARD is being added
Intervention: Add short-term GCs (≤ 3 months)
Comparator: Add long-term GCs (> 3 months)
No GCs added
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on DMARD(s) requiring GCs to remain at target, add a 2nd DMARD or switch to another DMARD to enable tapering off of GCs?
Population: Patients with RA on DMARD(s) requiring GCs to remain at target
Intervention: No change to management
Comparator: Switch to another DMARD
Add a 2nd DMARD
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?
Population: Patients with RA on their first TNF Inhibitor who are not at target
Intervention: Switch to a 2nd TNF Inhibitor
Comparator: Switch to Abatacept
Switch to Rituximab
Switch to IL-6 Receptor Inhibitor
Switch to JAK Inhibitor
Continue same management
Outcomes:
Switch to Abatacept: Disease activity (follow up: 1 year; assessed with: ACR 20)
Disease activity (follow up: 1 year; assessed with: ACR 50)
Disease activity (follow up: 1 year; assessed with: ACR 70)
Remission (follow up: 1 year; assessed with: DAS28-ESR <2.6)
Disease activity (follow up: 1 year; assessed with: DAS28-ESR (MCID -1.17))
Disability (follow up: 1 year; assessed with: HAQ-DI (MCID -0.22))
Quality of life (follow up: 1 year; assessed with: RAQol (MCID 2))
Pain (follow up: 1 year; assessed with: VAS 0-100 (MCID -11.9))
Serious adverse events (follow up: 1 year)
Withdrawal due to lack of efficacy (follow up: 1 year)
Withdrawal due to adverse events (follow up: 1 year)
Malignancy (follow up: 1 year)
Cardiovascular disease (follow up: 1 year)
Death (follow up: 1 year)
Switch to Rituximab: Disease activity (follow up: 1 year; assessed with: ACR 20)
Disease activity (follow up: 1 year; assessed with: ACR 50)
Disease activity (follow up: 1 year; assessed with: ACR 70)
Disease activity (follow up: 1 year; assessed with: DAS28 ESR (Lower values – > benefit) (MCID -1.17)
Remission (follow up: 1 year; assessed with: DAS28-ESR <2.6)
Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)
Quality of life (follow up: 1 year; assessed with: RAQol (Lower values – > benefit) (MCID 2)
Pain (follow up: 1 year; assessed with: VAS 0-100 (Lower values – > benefit) (MCID -11.9)
Serious adverse events (follow up: 1 year)
Withdrawal due to lack of efficacy (follow up: 1 year)
Withdrawal due to adverse events (follow up: 1 year)
Death (follow up: 1 year)
CVD (follow up: 1 year)
Malignancy (follow up: 1 year)
Switch to IL-6 Receptor Inhibitor: Disease activity (follow up: 6 months; assessed with: DAS 28-ESR)
Low disease activity (follow up: 6 months; assessed with: DAS28-ESR <3.2)
Pain (follow up: 6 months; assessed with: VAS 100)
Disability (follow up: 6 months; assessed with: HAQ-DI)
Withdrawal due to adverse events (follow up: 1 year)
Withdrawal due to lack of efficacy (follow up: 6 months)
Continue same management: Disease activity (follow up: 4 months; assessed with: ACR 20)
Disease activity (follow up: 4 months; assessed with: ACR 50)
Disease activity (follow up: 4 months; assessed with: DAS28-ESR)
Remission (follow up: 4 months; assessed with: DAS28-ESR <2.6)
Radiographic progression (follow up: 4 months; assessed with: Sharp/ van der Heijde)
Serious adverse events (follow up: 4 months)
Serious adverse events (from SR of harms)
Withdrawal due to adverse events (follow up: 4 months)
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on their 2nd TNF Inhibitor who are NOT at target, switch to a 3rd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?
Population: Patients with RA on their 2nd TNF Inhibitor who are not at target
Intervention: Switching to a 3rd TNF Inhibitor
Comparator: Switch to Abatacept
Switch to Rituximab
Switch to IL-6 Receptor Inhibitor
Switch to JAK Inhibitor
Continue same management
Outcomes:
Switch to Abatacept: Disease activity (follow up: 1 year; assessed with: ACR 20)
Disease activity (follow up: 1 year; assessed with: ACR 50)
Disease activity (follow up: 1 year; assessed with: ACR 70)
Remission (follow up: 1 year; assessed with: DAS28-ESR <2.6)
Disease activity (follow up: 1 year; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)
Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)
Quality of life (follow up: 1 year; assessed with: RAQol (Lower values – > benefit) (MCID 2)
Pain (follow up: 1 year; assessed with: VAS 0-100 (Lower values – > benefit) (MCID -11.9)
Serious adverse events (follow up: 1 year)
Withdrawal due to lack of efficacy (follow up: 1 year)
Withdrawal due to adverse events (follow up: 1 year)
Death (follow up: 1 year)
Malignancy (follow up: 1 year)
Cardiovascular disease (follow up: 1 year)
Serious adverse events (from SR of harms)
Switch to Rituximab: Disease activity (follow up: 6 months; assessed with DAS 28-ESR (Lower values – > benefit) (MCID -1.17)
Low disease activity (follow up: 6 months; assessed with DAS28 ≤ 3.2)
Disability (follow up: 1 year; assessed with HAQ-DI (Lower values – > benefit) (MCID -0.22 )
Withdrawal due to lack of efficacy (follow up: 1 year)
Withdrawal due to adverse events (follow up: 1 year)
Continue same management: Disease activity (follow up: 4 months; assessed with: ACR 20)
Disease activity (follow up: 4 months; assessed with: ACR 50)
Disease activity (follow up: 4 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)
Remission (follow up: 4 months; assessed with: DAS28-ESR <2.6)
Radiographic progression (follow up: 4 months; assessed with: Sharp/ van der Heijde (Lower values – > benefit) (MCID 4.6)
Serious adverse events (follow up: 4 months)
Withdrawal due to adverse events (follow up: 4 months)
Serious adverse events (from SR of harms)
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on their first IL-6 Receptor Inhibitor who are NOT at target, switch to a 2nd IL-6 Receptor Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?
Population: Patients with RA on their first IL-6 Receptor Inhibitor who are not at target
Intervention: Switch to a 2nd IL-6 Receptor Inhibitor
Comparator: Switch to Abatacept
Switch to Rituximab
Switch to TNF Inhibitor
Switch to JAK Inhibitor
Continue same management
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on their first JAK Inhibitor who are NOT at target, switch to a 2nd JAK Inhibitor or switch to a boDMARD?
Population: Patients with RA on their first JAK Inhibitor who are not at target
Intervention: Switch to a 2nd JAK Inhibitor
Comparator: Switch to Abatacept
Switch to Rituximab
Switch to TNF Inhibitor
Switch to IL-6 Receptor Inhibitor
Continue same management
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on DMARDs who are NOT at target receive IA corticosteroids alone or add/switch DMARDs or IA corticosteroids and add/switch DMARD(s)?
Population: Patients with RA on DMARDs who are not at target
Intervention: IA steroids
Comparator: Add/Switch DMARD(s)
IA steroids and add/switch DMARD(s)
Outcomes:
add/Switch DMARD(s): Disease activity (follow up: 3 months; assessed with: ACR 20)
Disease activity (follow up: 3 months; assessed with: ACR 50)
Disease activity (follow up: 3 months; assessed with: ACR 70)
Disease activity (follow up: 3 months; assessed with: DAS28-ESR)
Disability (follow up: 3 months; assessed with: HAQ-DI)
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on DMARDs who are in low disease activity gradually taper off DMARDs, abruptly withdraw DMARDs, or continue DMARDS at the same doses?
Population: Patients with RA on DMARDs who are in low disease activity
Intervention: Taper off DMARDs (as long as the patient remains on at least one DMARD)
Comparator: Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)
Continue DMARDs at same doses
Outcomes:
Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD): Disease activity (follow up: range 9 months to 12 months; assessed with: DAS28-ESR)
Flare (follow up: range 6 months to 12 months)
Radiographic progression (follow up: range 9 months to 12 months; assessed with: mTSS)
Fatigue (follow up: range 9 months to 12 months; assessed with: FACIT-F)
Quality of Life (follow up: 9 months; assessed with: SF-36 PCS)
Quality of Life (follow up: 9 months; assessed with: SF-36 MCS)
Disability (follow up: 12 months; assessed with: HAQ-DI)
Pain (follow up: 12 months; assessed with: VAS Pain)
Withdrawal due to lack of efficacy (follow up: 12 months)
Withdrawal due to adverse events (follow up: range 9 months to 12 months)
Serious adverse events (follow up: range 9 months to 12 months)
Malignancy (follow up: range 9 months to 12 months)
Death (follow up: 12 months)
Continue DMARDs at same doses: Disease activity (follow up: 1 year; assessed with: DAS28-ESR)
Flare (follow up: range 11 months to 18 months)
Radiographic progression (follow up: 1 year; assessed with: mTSS)
Fatigue (follow up: 1 year; assessed with: FACIT-F)
Pain (follow up: 1 year; assessed with: VAS pain (0-100))
Disability (follow up: 1 year; assessed with: HAQ-DI)
Withdrawal due to lack of efficacy (follow up: 1 year)
Withdrawal due to adverse events (follow up: 1 year)
Serious adverse events (follow up: 1 year)
Malignancy (follow up: 1 year)
Death (follow up: 1 year)
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on DMARDs who are in remission gradually taper off DMARDs, abruptly withdraw DMARDs, or continue DMARDS at the same doses?
Population: Patients with RA on DMARDs in remission
Intervention: Taper off DMARDs (as long as the patient remains on at least one DMARD)
Comparator: Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD)
Continue DMARDs at same doses
Outcomes:
Abruptly withdraw DMARDs (as long as the patient remains on at least one DMARD): Disease activity (follow up: 9 months; assessed with: ACR 20)
Disease activity (follow up: 9 months; assessed with: ACR 50)
Disease activity (follow up: 9 months; assessed with: ACR 70)
Disease activity (follow up: 9 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)
Remission (follow up: 9 months; assessed with: DAS28ESR < 2.6)
Flare (follow up: 12 months)
Radiographic progression (follow up: 9 months; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)
Quality of Life (follow up: 9 months; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)
Quality of Life (follow up: 9 months; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1)
Fatigue (follow up: 9 months; assessed with: FACIT-F (Higher values – > benefit) (MCID 15.9)
Withdrawal due to adverse events (follow up: 9 months)
Serious adverse events (follow up: 9 months)
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on two or more DMARDs who are at target for less than six months withdraw DMARDs or continue DMARDs?
Population: Patients with RA on two or more DMARDs at target for less than six months
Intervention: Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)
Comparator: Continue current therapy
Outcomes:
Continue current therapy: Disease activity (follow up: 1 year; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)
Remission (follow up: 1 year; assessed with: DAS28-ESR <2.6)
Flare (follow up: range 7 months to 12 months)
Radiographic progression (follow up: 1 year; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)
Fatigue (follow up: 1 year; assessed with: FACIT-F (Higher values – > benefit) (MCID 15.9)
Pain (follow up: 1 year; assessed with: VAS pain (0-100) (Lower values – > benefit) (MCID -11.9)
Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)
Quality of Life (follow up: 1 year; assessed with: EuroQol-5 (Higher values – > benefit) (MCID 0.1)
Withdrawal due to lack of efficacy (follow up: 1 year)
Withdrawal due to adverse events (follow up: 1 year)
Serious adverse events (follow up: 1 year)
Malignancy (follow up: 1 year)
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on two or more DMARDs who are at target for six months and longer withdraw DMARDs or continue DMARDs?
Population: Patients with RA on two or more DMARDs at target for six months and longer
Intervention: Withdraw one DMARD (or more than one DMARD as long as the patient remains on at least one DMARD)
Comparator: Continue current therapy
Outcomes:
Continue current therapy: Disease activity (follow up: 3 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)
Flare (follow up: range 11 months to 18 months)
Disability (follow up: 3 months; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on DMARDs and low dose GCs (≤ 10mg per day) who are at target taper off or continue low dose GCs?
Population: Patients with RA on DMARDs and low dose GCs (≤ 10mg per day) who are at target
Intervention: Taper off low dose GCs
Comparator: Continue low dose GCs
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on DMARD monotherapy who are in remission gradually taper off DMARD, abruptly withdraw DMARD, or continue DMARD at the same dose?
Population: Patients with RA on DMARD monotherapy who are in remission
Intervention: Taper off DMARD
Comparator: Abruptly withdraw DMARD
Continue DMARD at same dose
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on DMARD monotherapy who are in low disease activity gradually taper off DMARD, abruptly withdraw DMARD, or continue DMARD at the same dose?
Population: Patients with RA on DMARD monotherapy who are in low disease activity
Intervention: Taper off DMARD
Comparator: Abruptly withdraw DMARD
Continue DMARD at same dose
Outcomes:
Abruptly withdraw DMARD: Relapse (follow up: 1 year; assessed with DAS28 CRP>2.7 )
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on triple therapy (MTX + SSZ + HCQ) who are at target withdraw (taper off or abruptly stop) MTX or withdraw (taper off or abruptly stop) alternative csDMARDs?
Population: Patients with RA on triple therapy who are at target
Intervention: Withdraw (taper off or abruptly stop) MTX
Comparator: Withdraw (taper off or abruptly stop) alternative csDMARDs
Continue same management
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target withdraw (taper off or abruptly stop) MTX or withdraw (taper off or abruptly stop) the boDMARD or the tsDMARD?
Population: Patients with RA on MTX + boDMARD or MTX + tsDMARD who are at target
Intervention: Withdraw (taper off or abruptly stop) MTX
Comparator: Withdraw (taper off or abruptly stop) the boDMARD or the tsDMARD
Continue same management
Outcomes:
Continue same management: Disease activity (follow up: 3 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)
Disability (follow up: 3 months; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)
Quality of life (follow up: 3 months; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)
Quality of life (follow up: 3 months; assessed with:  SF-36 MCS (Higher values – > benefit) (MCID 3.1)
Serious adverse events (follow up: 3 months)
Withdrawal due to lack of efficacy (follow up: 3 months)
Withdrawal due to adverse events (follow up: 3 months)
Death (follow up: 3 months)
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on DMARD monotherapy who are at target lower the dose or increase the interval between doses or continue the DMARD at the same dose?
Population: Patients with RA on DMARD monotherapy in remission
Intervention: Continue DMARD at the same dose
Comparator: Lower the dose of the DMARD
Increase the interval between DMARD doses
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue MTX at the same dose or lower the dose of MTX? (boDMARD or tsDMARD continued at same dose)
Population: Patients with RA on MTX + boDMARD or tsDMARD who are at target
Intervention: Continue MTX at the same dose
Comparator: Lower the dose of MTX
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on MTX + boDMARD or tsDMARD who are at target continue the boDMARD or tsDMARD at the same dose or lower the dose or increase the interval between doses of the boDMARD or tsDMARD (MTX continued at same dose)?
Population: Patients with RA on MTX + boDMARD or tsDMARD who are at target
Intervention: Continue the same dose of the boDMARD or tsDMARD
Comparator: Lower the dose of the boDMARD or tsDMARD
Increase the interval between the doses of the boDMARD or tsDMARD
Outcomes:
lower the dose of the boDMARD or tsDMARD: Disease activity (follow up: range 6 months to 12 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)
Flare (follow up: range 6 months to 12 months)
Radiographic progression (follow up: range 6 months to 12 months; assessed with: Larsen/Sharp (Lower values – > benefit) (values > 0.2 are considered clinically important)
Fatigue (follow up: range 6 months to 12 months; assessed with: FACIT-F (Higher values – > benefit) (MCID 15.9)
Pain (follow up: range 6 months to 12 months; assessed with: VAS pain (0-100) (Lower values – > benefit) (MCID -11.9)
Disability (follow up: range 6 months to 12 months; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)
Quality of Life (follow up: range 6 months to 12 months; assessed with: EQ-5D (Higher values – > benefit) (MCID 0.1)
Withdrawal due to adverse events (follow up: 1 year)
Serious adverse events (follow up: range 6 months to 12 months)
Cardiovascular disease (follow up: 6 months)
Malignancy (follow up: 1 year)
Death (follow up: 1 year)
increase the interval between the doses of the boDMARD or tsDMARD: Disease activity (follow up: 3 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)
Flare (follow up: 18 months)
Disability (follow up: 3 months; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)
Guideline: 2021 ACR RA
Clinical question: Should patients with RA on MTX + boDMARD or tsDMARD who are at target lower the dose of MTX or lower the dose or increase the interval between doses of the boDMARD or tsDMARD?
Population: Patients with RA on MTX + boDMARD or tsDMARD who are at target
Intervention: Lower the dose of MTX
Comparator: Lower the dose of the boDMARD or tsDMARD
Increase the interval between doses of boDMARD or tsDMARD
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with (progressive) subcutaneous nodules, who are NOT at target and are not on MTX, start MTX or alternative DMARDs?
Population: Patients with RA and (progressive) subcutaneous nodules, who are not at target, are not on MTX
Intervention: Start MTX
Comparator: Start alternative csDMARD mono or combination therapy
Start TNF Inhibitor
Start Abatacept
Start Rituximab
Start IL-6 Receptor Inhibitor
Start JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with (progressive) subcutaneous nodules, who are at target and are on MTX, continue MTX or switch to alternative DMARD(s)?
Population: Patients with RA and (progressive) subcutaneous nodules who are at target and are on MTX
Intervention: Continue MTX
Comparator: Switch to alternative csDMARD mono or combination therapy
Switch to TNF Inhibitor
Switch to Abatacept
Switch to Rituximab
Switch to IL-6 Receptor Inhibitor
Switch to JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA who have persistent hypogammaglobulinemia after RTX treatment continue RTX or switch to csDMARD mono or combination therapy or to a boDMARD targeting a different molecule or to a tsDMARD?
Population: Patients with RA who have persistent hypogammaglobulinemia after RTX treatment
Intervention: Continue RTX
Comparator: Switch to csDMARD mono or combination therapy
Switch to TNF Inhibitor
Switch to Abatacept
Switch to IL-6 Receptor Inhibitor
Switch to JAK Inhibitor
Outcomes: